Managing Atrial Fibrillation During Pregnancy Safely

Atrial fibrillation (AF) during pregnancy is uncommon, but it can create difficult decisions involving maternal haemodynamics, fetal exposure to medicines, thromboembolic risk and the timing of delivery. The arrhythmia may occur in a woman with congenital heart disease, cardiomyopathy, valve disease, hyperthyroidism or hypertension, or it may appear in an otherwise healthy patient with a structurally normal heart.

Management should be individualised according to gestational age, ventricular rate, symptoms, haemodynamic status and the cause of AF. A stable patient may need careful observation and rate control, while hypotension, pulmonary oedema, myocardial ischaemia or fetal compromise can require urgent electrical cardioversion. Anticoagulation decisions also differ from routine AF practice because pregnancy changes coagulation physiology and exposes the fetus to potential drug effects.

In Australia, care is often shared between an obstetric physician, cardiologist or electrophysiologist, maternal-fetal medicine specialist, anaesthetist and neonatology team. Patients in Sydney, Melbourne, Brisbane, Perth and other major centres may access dedicated cardio-obstetric services, while regional patients may require telehealth review or transfer to a tertiary hospital. Early planning helps ensure that advice remains practical across public and private maternity settings.

Confirming The Rhythm And Cause

A 12-lead electrocardiogram should confirm AF and distinguish it from atrial flutter or another supraventricular tachycardia. Persistent palpitations warrant assessment of blood pressure, oxygen saturation, fluid status, signs of heart failure and fetal wellbeing. An echocardiogram can identify valve disease, atrial enlargement, ventricular dysfunction, pulmonary hypertension or congenital abnormalities that alter both rhythm and anticoagulation management.

Laboratory testing commonly includes a full blood count, electrolytes, renal function, magnesium and thyroid studies. Infection, anaemia, dehydration, pulmonary embolism, stimulant use and thyroid disease should be considered when the onset is sudden. A medication history is essential, including over-the-counter products and supplements used for nausea, sleep or weight control.

The duration of AF matters. A clearly documented onset of less than 48 hours may permit a different cardioversion pathway from AF of uncertain or longer duration. When the onset cannot be established, clinicians should avoid assuming that the episode is recent simply because symptoms began recently.

Rate Control And Medication Safety

For a stable patient, rate control may be achieved with a beta blocker, commonly metoprolol, when there is no significant asthma, bradycardia or ventricular dysfunction. Digoxin may be useful when beta blockade is inadequate or poorly tolerated. Verapamil or diltiazem can be considered in selected cases, although their use requires attention to maternal blood pressure, ventricular function and interactions with other medicines.

Drug selection should reflect placental transfer, fetal growth, neonatal effects and the trimester of exposure. Beta blockers may be associated with fetal growth restriction or neonatal bradycardia and hypoglycaemia, so fetal growth surveillance and neonatal observation may be appropriate. Digoxin crosses the placenta, but clinically useful maternal dosing is widely used when carefully monitored.

Flecainide or sotalol may be considered for rhythm control in selected patients, particularly when AF is recurrent or poorly tolerated. These medicines require specialist oversight, ECG assessment and attention to renal function and QT prolongation. Amiodarone is generally avoided because of fetal thyroid effects, growth concerns and potential neonatal complications, but it can have a role in life-threatening or otherwise refractory arrhythmia.

Atrial flutter or an accessory pathway changes the risk profile. AV nodal blockade can be hazardous in some pre-excitation syndromes, especially if rapid conduction occurs through an accessory pathway. Electrophysiology input is therefore important before selecting a rate-control drug when the ECG is atypical or the diagnosis remains uncertain.

Anticoagulation Across Pregnancy

Pregnancy is a prothrombotic state, and AF adds embolic risk through irregular atrial contraction and possible atrial enlargement. Standard risk scores such as CHA₂DS₂-VASc are useful starting points, but they do not fully capture pregnancy, congenital heart disease, valve lesions or cardiomyopathy. A specialist assessment should consider the individual clinical context rather than applying a score mechanically.

Low-molecular-weight heparin, such as enoxaparin, is commonly used because it does not cross the placenta. Weight-based dosing and, in selected circumstances, anti-Xa monitoring may be needed. Dose adjustments become relevant as maternal weight and renal function change. Australian hospitals generally have access to enoxaparin through established hospital and community pharmacy pathways, although prescribing arrangements can differ between states and health networks.

Unfractionated heparin may be preferred near delivery because it has a shorter duration of action and can be reversed more readily. Warfarin crosses the placenta and is associated with fetal risks, particularly during organ formation and near delivery, but it may remain necessary for some women with mechanical heart valves. This is a different and more complex situation from uncomplicated AF and requires a specialised anticoagulation plan.

Direct oral anticoagulants, including apixaban, rivaroxaban and dabigatran, are generally avoided during pregnancy because safety data are limited and placental or breastmilk exposure remains a concern. Anticoagulation should also be coordinated with neuraxial anaesthesia, planned induction and caesarean birth so that treatment is neither stopped unnecessarily nor continued too close to a procedure.

When Electrical Cardioversion Is Appropriate

Synchronized direct-current cardioversion is indicated when AF causes haemodynamic instability, pulmonary oedema, ongoing myocardial ischaemia, shock or severe symptoms that do not respond promptly to medical treatment. Pregnancy is not a contraindication. Maternal stabilisation is the priority because maternal hypoxaemia and reduced cardiac output can quickly threaten the fetus.

Cardioversion may also be reasonable in a stable patient when rapid restoration of sinus rhythm is clinically important, when rate control is ineffective or when AF persists with significant symptoms. The procedure should occur in a setting with obstetric, anaesthetic and neonatal support. Fetal heart-rate assessment before and after cardioversion is generally appropriate, with continuous monitoring when gestational age and local resources make it feasible.

Energy delivery is applied across the maternal chest, not the uterus, and available evidence has not shown a meaningful increase in fetal harm from appropriately performed cardioversion. Anaesthetic planning should account for aspiration risk, airway changes and the possibility of difficult ventilation in later pregnancy. The lowest effective sedative exposure and a clear recovery plan are sensible principles.

If AF has lasted more than 48 hours or its duration is uncertain, anticoagulation and thrombus assessment must be addressed before elective cardioversion. Transoesophageal echocardiography may help exclude left atrial thrombus in selected circumstances, but it does not eliminate the need for an overall anticoagulation strategy.

Rhythm Control And Catheter Procedures

Restoring sinus rhythm may be favoured when AF is poorly tolerated, recurrent, associated with structural heart disease or difficult to control with medication. Treatment should also address the trigger, such as thyrotoxicosis, infection, electrolyte disturbance or excessive alcohol. Australian patients may encounter different referral pathways depending on whether they receive care through a metropolitan public hospital, private cardiology practice or a regional service.

Catheter ablation is rarely undertaken during pregnancy and is generally deferred until after birth because fluoroscopy, anaesthesia and procedural stress create avoidable concerns. In exceptional, drug-refractory cases with severe instability, a highly experienced centre may consider zero- or near-zero-fluoroscopy ablation. This decision requires a detailed maternal-fetal risk assessment and electrophysiology expertise.

Experience with ablation in related supraventricular arrhythmias can inform procedural counselling, although it should not be transferred uncritically to pregnant patients. Reviews of ablation outcomes illustrate why age, comorbidity, anatomy and procedural indication must be considered when discussing efficacy and complications.

After delivery, rhythm management options broaden. A postpartum review should reassess the arrhythmia diagnosis, thyroid function, ventricular function, sleep, blood pressure, alcohol intake and breastfeeding considerations. Ablation may then be considered if AF or another atrial tachyarrhythmia remains symptomatic or recurrent.

Planning Labour And Birth

Most women with well-controlled AF can plan vaginal birth according to obstetric indications. AF alone is not an indication for caesarean delivery, and avoiding unnecessary surgery can reduce bleeding, infection and thrombotic risk. The birth plan should specify the preferred site of delivery, monitoring level, fluid strategy, analgesia, anticoagulant interruption and escalation pathway.

A woman with active AF, ventricular dysfunction, pulmonary hypertension, severe valve disease or previous decompensation may need delivery in a tertiary centre. In Australia, this may involve transfer from a regional maternity unit to a cardiac-obstetric service in a capital city. The plan should account for retrieval logistics, family support, bed availability and the possibility that labour begins before a scheduled admission.

Anticoagulant timing is central to neuraxial anaesthesia. Low-molecular-weight heparin usually needs to be withheld for an interval based on dose and local anaesthetic guidance, while unfractionated heparin may offer greater flexibility near birth. Decisions should be documented well before labour, with instructions that remain understandable to the patient, midwives, emergency clinicians and anaesthesia team.

Continuous maternal ECG or telemetry is appropriate for selected high-risk patients rather than automatically for every woman with a remote, stable episode. Fetal monitoring should follow obstetric risk and gestational age. A postpartum haemorrhage plan is also important because anticoagulation may need to restart soon after birth while bleeding risk is still changing.

Postpartum Surveillance And Future Pregnancy

The early postpartum period is haemodynamically dynamic. Autotransfusion from the contracting uterus, fluid shifts, pain, anaemia, infection and sleep deprivation can precipitate recurrent AF or heart failure. Monitoring should be more intensive for women with reduced ventricular function, significant valve disease, previous cardioversion or ongoing anticoagulation.

Medication review after birth should include breastfeeding. Some drugs are compatible with lactation at usual doses, while others require specialist advice or an alternative. Anticoagulation may need to continue according to the woman’s thromboembolic risk and the persistence of AF, rather than stopping automatically after delivery.

Follow-up should include ECG review, echocardiography where indicated and assessment for reversible causes. Women who may want another pregnancy benefit from a preconception consultation covering rhythm stability, anticoagulant choice, weight, blood pressure and any planned ablation. Clear written records are especially valuable when care moves between a general practitioner, community midwife, private obstetrician and hospital cardiology team.

The field of cardiac rhythm care continues to evolve, including device-based strategies for patients who later develop bradyarrhythmia or require pacing. Experience reported in leadless pacemaker experience is relevant to broader discussions about long-term device management, although leadless systems have no routine role in uncomplicated AF during pregnancy.

Clinical decisions should be made by the treating team with access to the patient’s examination, ECG, imaging, gestational age and medication history. Journal of Arrhythmia provides an open-access forum for current evidence in electrophysiology, ablation, pacing and pharmacology. Clinicians and researchers seeking publication or educational resources can contact the Journal contact team for information about submissions and journal services.